This Journal of Hematology & Oncology series covers bi-specific T-cell engagers (BiTE) and antibody-drug conjugates (ADCs) for cancer therapy. The series, which is no longer open for submissions, will include reviews, editorials, and first in-human clinical trial papers.
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities has become a promising strategy in clinical management of hematologic malignancies. The emerging bispecific antibodies...